Palazzo della Borsa della Camera di Commercio Firenze





# FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025





### President of the Meeting Alessandro Maria Vannucchi

# Scientific Secretariat Paola Guglielmelli Francesco Mannelli Chiara Paoli Valeria Santini

#### Organizing Secretariat / CME Provider

AVEC S.r.l.- Incentive Paintings Via Lavoratori Autobianchi, 1 20832 Desio (MB, Italy) Phone: +39 0362 581579 info@avec-eventi.com www.avec-eventi.com





### With the Patronage of



Da un secolo, oltre.







### SIE Società Italiana di Ematologia





## FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025

### Introduction

Hematology is a continuously changing discipline virtuously standing half the way between the bench and the bed. It is continuously informed by advancements in genetics and pathophysiology that, at a sometimes incredible pace, translated into diagnostic, prognostic and therapeutic benefits for the patients. The third edition of the Florence Symposium "From genes to targeted therapy in hematology" will host international KOL presenting the latest news in oncologic and non-oncologic hematologic diseases with the aim to boost knowledge and interactions among participants.

Alessandro Maria Vannucchi

### FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025

### Program



### 1<sup>st</sup> DAY NOVEMBER 6<sup>th</sup>, 2025

01:50 p.m. - 01:55 p.m. **A.M. Vannucchi** (Florence, IT)

Welcome and Introduction

01:55 p.m. - 02:10 p.m. L. Galbiati (Milan, IT)

"From Genes to Target Therapy in Hematology": Managing the scientific

research in Italy



Session I: Acute leukemias I

Chairperson: A. M. Vannucchi (Florence, IT)

02:10 p.m. - 02:30 p.m. N. Daver (Houston, USA)

Venetoclax: a "passpartout" for AML?

02:30 p.m. - 02:50 p.m. **L. Bullinger** (Berlin, DE)

TP53 AML: How to manage

02:50 p.m. - 03:00 p.m. **Panel discussion** 

**INFOCUS 1** 

03:00 p.m. - 03:30 p.m. **A. Bacigalupo** (Rome, IT)

Introduction

M. Heuser (Hannover, DE)

Management of MRD pre and post

allotransplant for AML

**INFOCUS 2** 

03:30 p.m. - 04:00 p.m. **C. Nozzoli** (Florence, IT)

Introduction

P. Corradini (Milan, IT)

Efficacy and long-term complications of CAR-T cells for lymphomas



**INFOCUS3** 

04:00 p.m. - 04:30 p.m. M. Della Porta (Milan, IT)

Introduction

A. Tefferi (Rochester, USA)

CMML: how to prognosticate

and manage in 2025

04:30 p.m. - 04:50 p.m. Coffee break

04:50 p.m. - 05:20 p.m. Selected oral communications

Chairperson: A.M. Vannucchi (Florence, IT)

Session II: Chronic Myeloproliferative Neoplasms

Chairperson: A. Tefferi (Rochester, USA)

05:20 p.m. - 05:40 p.m. **N. Gangat** (Rochester, USA)

MPN as a model for gender medicine

05:40 p.m. - 06:00 p.m. F. Passamonti (Milan, IT)

Therapies for myelofibrosis:

the near future

06:00 p.m. - 06:20 p.m. A. Reiter (Mannheim, DE)

Target therapies for mastocytosis and

clonal eosinophilias

06:20 p.m. - 06:30 p.m. **Panel discussion** 

### 1<sup>st</sup> DAY NOVEMBER 6<sup>th</sup>, 2025



### **INFOCUS**4

06:30 p.m. - 07:00 p.m.

F. Mannelli (Florence, IT)

Introduction

C. Craddock (Birmingham, UK)

What's moving on in clinical trials for AML

### 2<sup>nd</sup> DAY NOVEMBER 7<sup>th</sup>, 2025



### Session III: Hot topics I

Chairperson: M. Cazzola (Pavia, IT)

08:30 a.m. - 08:50 a.m.

L. Malcovati (Pavia, IT)

SF3B1 myeloid neoplasms

08:50 a.m. - 09:10 a.m.

L. Gondek (Baltimore, USA)

Progression from CHIP to myeloid neoplasms

09:10 a.m. - 09:20 a.m.

Panel discussion

### IN FOCUS 5

09:20 a.m. - 09:50 a.m.

P. Ghia (Milan, IT)

Introduction

D. Rossi (Bellinzona, SW)

**CLL:** New therapeutical strategies





Session IV: Acute Leukemias II

Chairperson: M.P. Martelli (Perugia, IT)

09:50 a.m. - 10:10 a.m. N. Gangat (Rochester, USA)

Are all goals in Blastic Plasmacytoid Dendritic Cell Neoplasm met?

10:10 a.m. - 10:30 a.m. **R. Rampal** (New York, USA)

Secondary and therapy-related AML:

moving field?

10:30 a.m. - 10:50 a.m. A. Rambaldi (Bergamo, IT)

Can ALL be cured with immunotherapies?

10:50 a.m. - 11:00 a.m. **Panel discussion** 

11:00 a.m. - 11:20 a.m. **Coffee break** 

IN FOCUS 6

11:20 a.m. - 11:50 a.m. **V. Santini** (Florence, IT)

Introduction

C. Gurnari (Rome, IT)

**VEXAS Syndrome** 

### 2<sup>nd</sup> DAY NOVEMBER 7<sup>th</sup>, 2025





### Session V: Multiple Myeloma Chairperson: N. Giuliani (Parma, IT)

11:50 a.m 12:10 p.m.	F. Gay (Turin, IT)
-	MRD as a biomarker for
	treatment decision

- 12:10 p.m. 12:30 p.m.

  E. Zamagni (Bologna, IT)

  Novel approved drugs for multiple myeloma
- 12:30 p.m. 12:40 p.m. **Panel discussion**

### IN FOCUS 7 12:40 p.m. -

12:40 p.m. - 01:10 p.m.

P. Guglielmelli (Florence, IT)
Introduction

E. Duncavage (St. Louis, USA)
Omics in the advanced practice
of AML patients

- 01:10 p.m. 01:40 p.m. Lunch
- 01:40 p.m. 02:10 p.m. Selected oral communications
  Chairperson: A.M. Vannucchi (Florence, IT)







**Session VI:** : Lymphomas

Chairperson: M. Ladetto (Alessandria, IT)

02:10 p.m. - 02:30 p.m. S. Horwitz (New York, USA)

Linfomi T

02:30 p.m. - 02:50 p.m. **J. Ferdinandus** (Cologne, DE)

Hodgkin lymphoma management

in 2025

02:50 p.m. - 03:10 p.m. **M. Ladetto** (Alessandria, IT)

Mantle cell lymphoma in 2025

03:10 p.m. - 03:20 p.m. **Panel discussion** 

**INFOCUS8** 

03:20 p.m. - 03:50 p.m. **E. Antonioli** (Florence, IT)

Introduction

G. Palladini (Pavia, IT)

AL amyloidosis: diagnosis and

management

03:50 p.m. - 04:10 p.m. **Coffee break** 

### 2<sup>nd</sup> DAY NOVEMBER 7<sup>th</sup>, 2025





### Session VII: Hot Topics II Chairperson: T. Mughal (Boston, USA)

04:10 p.m 04:30 p.m.	T. Barbui (Bergamo, IT) New therapeutic end-points and new agents for polycythemia vera
04:30 p.m 04:50 p.m.	E. Gavriilaki (Thessaloniki, GR)


			es in under naging PN	rstanding H	
0.4.70	0 7 4 0	C P	(75)	TIGAL	

C. Brugnara (Boston, USA)		
e cell anemia		

05:10 p.m 05:30 p.m.	F. Locatelli (Rome, IT)
	Gene therapy in hemoglobinopathy

05:30 p.m 05:50 p.m.	<b>J. Martínez-López</b> (Madrid, ES)
	CAR-T in myeloma

•	Closure of the meeting
05:50 p.m 06:00 p.m.	A. M. Vannucchi (Florence, IT)



### FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025

### Faculty List



Edition 2025

### **Faculty List**

Elisabetta Antonioli (Florence, Italy)

Andrea Bacigalupo (Rome, Italy)

Tiziano Barbui (Bergamo, Italy)

Carlo Brugnara (Boston, USA)

Lars Bullinger (Berlin, Germany)

Mario Cazzola (Pavia, Italy)

Paolo Corradini (Milan, Italy)

Charlie Craddock (Birmingham, United Kingdom)

Naval Daver (Houston, USA)

Matteo Della Porta (Milan, Italy)

Eric Duncavage (Sant Louis, USA)

Justin Ferdinandus (Cologne, Germany)

Laura Galbiati (Milan, Italy)

Naseema Gangat (Rochester, USA)

Eleni Gavriilaki (Thessaloniki, Greece)

Francesca Gay (Turin, Italy)

Paolo Ghia (Milan, Italy)

Nicola Giuliani (Parma, Italy)

Lukasz Gondek (Baltimore, USA)

Paola Guglielmelli (Florence, Italy)

Carmelo Gurnari (Rome, Italy)



Edition 2025

### **Faculty List**

Michael Heuser (Hannover, Germany)

Steven Horwitz (New York, USA)

Marco Ladetto (Alessandria, Italy)

Franco Locatelli (Rome, Italy)

Luca Malcovati (Pavia, Italy)

Francesco Mannelli (Florence, Italy)

Maria Paola Martelli (Perugia, Italy)

Joaquín Martínez-López (Madrid, Spain)

Tariq Mughal (Boston, USA)

Chiara Nozzoli (Florence, Italy)

Giovanni Palladini (Pavia, Italy)

Francesco Passamonti (Milan, Italy)

Alessandro Rambaldi (Bergamo, Italy)

Raajit Rampal (New York, USA)

Andreas Reiter (Mannheim, Germany)

Davide Rossi (Bellinzona, Switzerland)

Valeria Santini (Florence, Italy)

Ayalew Tefferi (Rochester, USA)

Alessandro Maria Vannucchi (Florence, Italy)

Elena Zamagni (Bologna, Italy)

# FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025

### General Info



### General Info

#### **Meeting venue**

#### Palazzo della Borsa della Camera di Commercio

Piazza Mentana, 1-2 – 50122 Florence

### Registrations

No registration fee is required to attend the meeting

### Online Registration available at the following link:

https://targettherapyinhematology.com/

### Official language

English. Simultaneous translation will not be provided

### **Continuing Medical Education (CME) credits**

The application for CME accreditation has been submitted to the Italian Ministry of Health for Italian Physicians (disciplines: pathological anatomy, hematology, medical genetics, laboratory of medical genetics, internal medicine, transfusion medicine, oncology)

### **In-person Congress**

• CME provider AVEC: ID 2299 - 458155

• Nr. CME credits: 12

The CME credits will be awarded only after 90% attendance of all sessions. In order to obtain CME credits it is necessary to fill in the evaluation form and the Learning Questionnaire at the end of the event.

The CME Certificate is based on the real-time tracked spent attending Scientific Sessions.

Upon completion of the training course, a CME Certificate will be available online.

Edition 2025



#### **Badge and Certificate of attendance**

Each participant receives a name badge upon check-in at the registration desk (with proof of original registration). This badge should be worn all times in order to gain access to the session room and will be scanned at the entrance.

Please note that access to the congress areas will not be permitted without an official congress badge.

The Certificate of Attendance will be available online at the end of the event.

#### **Technical facilities**

A Slide Centre with PCs (Windows and Macintosh operating systems) will be available for Speakers to check and preview their presentations. Speakers are kindly requested to submit their presentations on USB flash drive to the Slide Centre technicians at least one hour before the opening of the Session.

#### Lunch and coffee breaks

Lunch and coffee breaks will be provided at the Conference premises.

Edition 2025

### Come destinare il 5 per mille ad AIRC

I modelli per la dichiarazione dei redditi CU, 730 e UNICO contengono uno spazio dedicato al 5 per 1000. Nella sezione relativa al Finanziamento della ricerca scientifica e della universita' puoi firmare e indicare il codice fiscale di AIRC 80051890152.



Finanziamento della ricerca scientifica e dell'università		
FIRMA Mario Ro	, 055i	
Codice fiscale del beneficiario (eventuale)	80051890152	

# With the unconditional educational grant from:

# FROM GENES TO TARGET THERAPY IN HEMATOLOGY

Edition 2025

